liplacis

LiPlaCis is a liposomal formulation of cisplatin, a well-established chemotherapy agent. This innovative drug delivery system enables precise targeting of tumor sites, potentially improving efficacy while reducing the toxicity typically associated with conventional cisplatin therapy. ## Drug Information LiPlaCis is designed to be degraded by secretory phospholipase A2 (sPLA2), an enzyme overexpressed in several types of tumors. This targeted mechanism ensures that cisplatin is released specifically in cancer cells expressing the enzyme, while sparing healthy tissues that don't express sPLA2[5]. The drug has been developed primarily for metastatic breast cancer, with clinical trials showing promising results. In a Phase 2 study, the cisplatin-DRP (Drug Response Predictor) companion diagnostic successfully identified all four metastatic breast cancer patients who demonstrated partial responses to LiPlaCis treatment[7]. ## Development History LiPlaCis was initially developed by LiPlasome Pharma ApS, which unfortunately went bankrupt after the initial phases of clinical testing[5][9]. The program was later continued by Oncology Venture (now known as Allarity Therapeutics), which received FDA approval for an Investigational Device Exemption (IDE) application for the LiPlaCis DRP companion diagnostic in 2019[1]. In June 2020, Oncology Venture signed an agreement to out-license LiPlaCis to Smerud Medical Research International for further clinical and commercial development. Under this agreement, Oncology Venture would receive regulatory milestone fees of nearly US $30 million plus royalties on sales if all milestones were met[2]. As of 2022, LiPlaCis was in Phase 2 development for metastatic breast cancer[4]. The Danish Medicines Agency had also approved an expansion of LiPlaCis development to include prostate cancer[8]. canonical_name: liplacis code_names: [] brand_names: ["LiPlaCis"] other_names: [] description: LiPlaCis is a third-generation intelligent liposomal formulation of cisplatin, enabling direct delivery to tumor sites. It is designed to be degraded by secretory phospholipase A2 (sPLA2), an enzyme overexpressed in several types of tumors, ensuring targeted release of cisplatin specifically in cancer cells while sparing healthy tissues. The drug is being developed in combination with a specific drug response predictor, LiPlaCis DRP, which includes 205 genes and predicts treatment response in individual patients based on a pre-treatment biopsy. developers: ["LiPlasome Pharma", "Oncology Venture", "Allarity Therapeutics"] manufacturers: ["Smerud Medical Research", "Chosa Oncology"] is_class: false class: null is_dietary_supplement: false is_pharmaceutical: true is_drug: true is_incorrect: false is_combination: false modalities: ["Small molecule", "Liposomal formulation"] mechanisms: [ { "target_name": "DNA", "abbreviation": null, "action_type": "inhibitor" } ] broad_active_ingredient: "cisplatin" biosimilar_of: null generic_of: null formulation_of: ["cisplatin"] contains: ["cisplatin"] comments: LiPlaCis was initially developed by LiPlasome Pharma, which went bankrupt after initial clinical trials. The program was later continued by Oncology Venture (now Allarity Therapeutics), which received FDA IDE approval for the LiPlaCis DRP companion diagnostic in 2019. In 2020, Allarity out-licensed LiPlaCis to Smerud Medical Research International. The drug is being developed alongside a companion diagnostic (LiPlaCis DRP) that predicts which patients will respond to treatment. development_status: {"Breast Cancer": "PHASE2", "Prostate Cancer": "IN DEVELOPMENT"} process: I analyzed the search results to extract information about LiPlaCis. I identified that it's a liposomal formulation of cisplatin developed initially by LiPlasome Pharma and later by Oncology Venture (now Allarity Therapeutics). I found that it's primarily being developed for metastatic breast cancer and is in Phase 2 trials for this indication. I also found mention of its development being expanded to prostate cancer. The mechanism of action involves DNA inhibition (as cisplatin is a DNA inhibitor) and targeted delivery via liposomes that are degraded by sPLA2 enzymes overexpressed in tumors. In 2020, the drug was out-licensed to Smerud Medical Research International. other_diseases: []

Brand names

LiPlaCis